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Abstract 
XRCC2 is one of five somatic RAD51 paralogs, all 
of which have Walker A and B ATPase motifs. 
Each of the paralogs, including XRCC2, has a 
function in DNA double-strand break repair by 
homologous recombination (HR). However, their 
individual roles are not as well understood as that 
of RAD51 itself.  
The XRCC2 protein forms a complex (BCDX2) 
with three other RAD51 paralogs, RAD51B, 
RAD51C and RAD51D. It is believed that the 
BCDX2 complex mediates HR downstream of 
BRCA2 but upstream of RAD51, as XRCC2 is 
involved in the assembly of RAD51 into DNA 
damage foci. XRCC2 can bind DNA and, along 
with RAD51D, can promote homologous pairing in 
vitro. Consistent with its role in HR, XRCC2-
deficient cells have increased levels of spontaneous 
chromosome instability, and exhibit 
hypersensitivity to DNA interstrand crosslinking 
agents such as mitomycin C and cisplatin as well as 
ionizing radiation, alkylating agents and aldehydes. 
XRCC2 also functions in promoting DNA 
replication and chromosome segregation.  
Biallelic mutation of XRCC2 (FANCU) causes the 
FA-U subtype of FA, while heterozygosity for 
deleterious mutations in XRCC2 may be associated 
with an increased breast cancer risk. XRCC2 
appears to function 'downstream' in the FA 
pathway, since it is not required for FANCD2 
monoubiquitination, which is the central step in the 
FA pathway.  
Clinically, the only known FA-U patient in the 
world exhibits severe congenital abnormalities, but 
had not developed, by seven years of age, the bone 
marrow failure and cancer that are often seen in 
patients from other FA complementation groups. 
Keywords 
Fanconi anemia, Breast Cancer Susceptibility, 
Tumor Suppressor, Homologous Recombination, 
DNA Repair, RAD51 Paralog 
Identity 
Other names: FANCU 
HGNC (Hugo): XRCC2 
Location: 7q36.1 
Local order 
As outlined by NCBI (Gene), coding genes located 
most proximal to XRCC2 on 16p12.2, in the 
centromeric to telomeric direction, are GALNTL5 
(polypeptide N-acetylgalactosaminyltranserase like 
5), GALNT11 (polypeptide N-
acetylgalactosaminyltransferase 11), KMT2C 
(lysine methyltransferase 2C), XRCC2, ACTR3B 
(ARP3 actin related protein 3 B homolog B), DPP6 
(dipeptidyl peptidase like 6), and LOC107984014. 
DNA/RNA 
In a screen for X-ray sensitive cellular mutants in 
Chinese hamster ovary (CHO) cells, the irs1 clone, 
which was thought to be deficient in a novel DNA 
repair gene, was obtained (Jones et al., 1987).  
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Exon structure of the human XRCC2 gene. Exons are delineated by a vertical black line. For each exon, coding sequence is 
shown in grey, while non-coding sequence in exons 1 and 3 is displayed in white. 
 
Two groups subsequently mapped the region 
containing the defective gene to 7q36.1 in humans 
based on somatic cell hybrids capable of 
complementing the hypersensitivity of irs1 cells to 
the DNA interstrand crosslinking agent mitomycin 
C (MMC) (Jones et al., 1995; Thacker et al., 1995). 
The human cDNA was subsequently identified as a 
novel gene with considerable homology on the 
protein level to the RAD51 recombinase (Liu et al., 
1998). The single protein coding human mRNA 
transcript (XRCC2-201), with a length of 3067 bp, 
has three coding exons (for a protein of 280 a.a.) 
arranged as shown below: 
Description 
The human XRCC2 gene locus is 29.66 kb in 
length. 
Transcription 
The single full-length transcript for human XRCC2 
is 3,067 bp and there are no additional confirmed 






The five somatic mammalian RAD51 paralogs, 
RAD51B, RAD51C, RAD51D, XRCC2 and 
XRCC3, form two prominent paralog-only protein 
complexes. These are the RAD51B-RAD51C-
RAD51D-XRCC2 (BCDX2) and RAD51C-
XRCC3 (CX3) complexes (Liu et al., 2002; 
Masson et al., 2001). RAD51C, which like XRCC2 
is a FA protein, is the only member of both 
complexes. As demonstrated using a yeast 2-hybrid 
assay, XRCC2 directly binds RAD51D within the 
BCDX2 complex (Schild et al., 2000). Further, 
experiments with purified proteins expressed in 
insect cells indicate that RAD51D bridges RAD51C 
and XRCC2 together (Schild et al., 2000). The 
RNF138 E3 ubiquitin ligase appears to regulate the 
interaction of RAD51D with XRCC2 by 
ubiquitinating RAD51D and promoting ubiquitin-
mediated degradation of this RAD51 paralog (Yard 
et al., 2016). XRCC2 itself regulates the abundance 
of the BCDX2 complex, since the RAD51B, 
RAD51C and RAD51D proteins display decreased 
stability in the absence of XRCC2 (Park et al., 
2016).  
Other proteins, including RAD51 (Rodrigue et al., 
2006) and HELQ, directly interact with the 
assembled BCDX2 complex (Adelman et al., 2013; 
Takata et al., 2013). It has also been reported that 
the BLM helicase interacts with the RAD51D-
XRCC2 complex via direct binding to RAD51D 
(Braybrooke et al., 2003).  
XRCC2 is essential for normal development in 
mice, as disruption of the Xrcc2 gene results in 
embryonic lethality ranging from mid-gestation to 
birth (Deans et al., 2000). 
Description 
While each of the five somatic RAD51 paralogs in 
humans has a somewhat similar size as RAD51, the 
paralogs show relatively low homology to RAD51. 
Specifically, the human XRCC2 protein has a size 
of 34 kD while human RAD51 has a molecular 
mass of 37 kD; human XRCC2 is 20% identical to 
human RAD51 at the amino acid level (Liu et al., 
1998).  
Still, each of the RAD51 paralogs, including 
XRCC2, shares Walker A and Walker B ATPase 
motifs with RAD51. The Walker A and Walker B 
motifs in human XRCC2 are present at a.a. 48-55 
and 145-149, respectively (Miller et al., 2004), as 
shown below. No other functional domains have 
been identified in XRCC2. 
Expression 
According to the Human Protein Atlas (online), 
XRCC2 mRNA is expressed in cell lines 
representing a variety of tissue types, including the 
brain, skin, myeloid and lymphoid compartments, 
lung, breast and kidney.  
The transcription factors MYC and ZNF281 bind to 
the XRCC2 promoter (Luoto et al., 2010; 
Pieraccioli et al., 2016).  
Further, it has been demonstrated that ZNF281 
positively regulates XRCC2 expression (Pieraccioli 
et al., 2016).  
Additionally, EZH2, a subunit of the PRC2 
transcriptional repressor complex, may have a role 
in downregulating XRCC2 expression, as increased 
expression of EZH2 in breast cancer cells is 
associated with epigenetic repression of XRCC2 
and other RAD51 paralogs (Zeidler and Kleer, 
2006). 
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Known functional domains present in XRCC2: the Walker A and B ATPase motifs are diagramed in black. 
 
Localisation 
Consistent with its role in DNA repair, XRCC2 is a 
nuclear protein (O'Regan et al., 2001). When 
assayed by immunofluorescence microscopy and 
chromatin immunoprecipitation, XRCC2 localizes 
to engineered DNA double-strand breaks (DSBs) in 
nuclei (Rodrigue et al., 2006). RAD51C also 
colocalizes with γ-H2AX in nuclear foci induced by 
etoposide (Rodrigue et al., 2006). Aside of its 
nuclear localization, XRCC2 also localizes to 
centrosomes within the cytoplasm (Cappelli et al., 
2011). 
Function 
Each of the five somatic RAD51 paralogs, 
including XRCC2, is required for DNA repair by 
homologous recombination (HR) (Johnson et al., 
1999; Takata et al., 2001). However, the role of 
XRCC2 and other RAD51 paralogs in promoting 
HR is less well understood than that of RAD51, 
which is the main mammalian recombinase. Still, 
molecular details concerning the role of XRCC2 in 
HR are emerging. For example, XRCC2 and other 
RAD51 paralogs appear to act upstream of RAD51 
and regulate its assembly into nuclear foci (Chun et 
al., 2013; Park et al., 2016; Patel et al., 2017; 
Takata et al., 2001). Further, purified XRCC2 can 
stimulate the ATPase activity of RAD51, thereby 
promoting the stability of the RAD51 oligomer and 
enhancing RAD51-dependent strand exchange 
during HR (Shim et al., 2004). While it is currently 
unclear whether this function of XRCC2 occurs 
within the context of the BCDX2 complex, the 
presence of XRCC2 favors short-tract gene 
conversion over long-tract gene conversion 
(Nagaraju et al., 2009). Interestingly, work in 
Arabidopsis thaliana has demonstrated the 
existence of a RAD51-independent single-strand 
annealing (SSA) mechanism involving XRCC2, 
RAD51B and RAD51D (Serra et al., 2013); like 
HR, SSA is also a homology-dependent form of 
DNA repair. XRCC2 could also play a more direct 
role in HR than what is described above, since 
purified XRCC2 and RAD51D can stimulate 
homologous pairing of single-strand DNA with 
double-strand DNA in vitro (Kurumizaka et al., 
2002).  
Additional data suggests that XRCC2 functions in 
HR in the context of the previously mentioned 
BCDX2 protein complex. The fact that the BCDX2 
complex binds Holliday junctions in vitro  
(Yokoyama et al., 2004) supports this possibility. 
BRCA2, which also regulates the assembly of 
RAD51 foci, appears to be epistatic with the 
BCDX2 complex in mediating HR (Chun et al., 
2013).  
The BCDX2 complex also binds to replication 
forks in vitro (Yokoyama et al., 2004). In support of 
a function in rescuing stalled or collapsed 
replication forks, XRCC2-deficient cells display 
compromised replication fork dynamics (Daboussi 
et al., 2008). This is consistent with the fact that HR 
is known to function in promoting the stability and 
rescue of arrested replication forks (Kolinjivadi et 
al., 2017).  
As a mediator of HR, XRCC2 also suppresses 
spontaneous chromosome abnormalities including 
breaks, deletions and translocations (Cui et al., 
1999; Takata et al., 2001).  
Also, related to its function in HR, XRCC2-
deficient cells are hypersensitive to a variety of 
DNA damaging agents that directly or indirectly 
yield DNA double-strand breaks, including ionizing 
radiation, DNA interstrand crosslinking agents such 
as mitomycin C (MMC) and cisplatin, aldehydes, 
tirapazamine and temozolomide (Evans et al., 2008; 
Jones et al., 1987; Park et al., 2016; Roos et al., 
2009; Zheng et al., 2012). Another function of 
XRCC2 that is potentially related to HR is in 
promoting accurate chromosome segregation and 
preventing mitotic catastrophe (Cappelli et al., 
2011; Daboussi et al., 2005; Griffin et al., 2000). 
However, it has been reported that XRCC2 
localizes to centrosomes and it is possible that 
polyploidy or aneuploidy observed in XRCC2-
deficient cells is associated with supernumerary 
centrosomes rather than a DNA repair defect 
(Cappelli et al., 2011; Daboussi et al., 2005; Griffin 
et al., 2000).  
Associated with its function in HR, XRCC2 also 
plays an essential role in promoting normal 
development (Deans et al., 2000). This includes a 
function in promoting normal lymphocyte 
development (Caddle et al., 2008). Also, XRCC2 
promotes survival of proliferating neural precursors 
in vivo (Orii et al., 2006). 
Homology 
Based on HomoloGene (NCBI), the following are 
homologs of the human XRCC2 gene 
(NP_005422.1, 280 a.a.):  
Chimpanzee (Pan troglodytes) XP_001140134.1, 
280 a.a.  
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Rhesus monkey (Macaca mulatta) 
XP_001108141.1, 280 a.a.  
Dog (Canis lupus familiaris) XP_532771.3, 279 a.a.  
Cattle (Bos taurus) NP_001095824.1, 280 a.a.  
Mouse (Mus musculus) NP_065595.2, 278 a.a.  
Rat (Rattus norvegicus) NP_001102685.1, 278 a.a.  
Chicken (Gallus gallus) XP_418543.3, 278 a.a.  
Tropical Clawed Frog (Xenopus tropicalis) 
XP_002932541.2, 282 a.a. 
Mutations 
Note 
Generally, germ-line alterations in XRCC2 are 
quite rare. In the largest study to date, of 13,087 
breast cancer and 5,488 control cases from the UK, 
a total of 11 truncating and 32 rare missense 
variants were found (Decker et al., 2017). A recent 
study functionally characterized breast cancer-
associated variants and found that each of the 
truncating or frameshift variants displayed 
compromised activity, while most of the missense 
variants tested displayed a minor change or no 
change in activity (Hilbers et al., 2016). Notably, a 
bi-allelic germ-line nonsense mutation in XRCC2 
c.643C>T encoding p.R215X is causative for the U 
complementation group of Fanconi anemia, FA-U 
(Park et al., 2016; Shamseldin et al., 2012).  
XRCC2 was initially published as a low-risk breast 
cancer susceptibility gene, similar to other late FA 
genes such as BRCA1, BRCA2, PALB2 and 
RAD51C (Park et al., 2012). However, subsequent 
studies could not confirm these findings and also 
presented data that the initial missense 
classification based on bioinformatic prediction 
tools was not correct (see below -> Breast Cancer) 
(Decker et al., 2017; Hilbers et al., 2012; Pelttari et 
al., 2015). 
Epigenetics 
Increased levels of the PRC2 subunit, EZH2, leads 
to epigenetic repression of XRCC2 in breast cancer 
cells (Zeidler and Kleer, 2006). Additionally, miR-
7 interacts with XRCC2 mRNA in colorectal cancer 
cells; overexpression of miR-7 reduces XRCC2 
promoter activity (Xu et al., 2014). Interestingly, 
XRCC2 promoter activity seems to be highly up-
regulated in nearly all types of cancers (Chen et al., 
2018). 
Implicated in 
Fanconi Anemia (FA) 
Note 
Germ-line bi-allelic and heterozygous mutations of 
XRCC2 (FANCU) are associated with different 
outcomes. Bi-allelic inactivating mutation of 
XRCC2 results in the FA-U subtype, while 
heterozygous inheritance of pathogenic XRCC2 
mutations might increase the lifetime risk of germ-
line mutation carriers for developing breast cancer. 
Disease 
Using whole exome sequencing, bi-allelic 
mutations in RAD51C were found in a 2.5 year old 
boy born to healthy Saudi first cousins with a 
spectrum of severe congenital anomalies suggestive 
of FA. These included microcephaly, facial palsy, a 
lack of thumbs, short stature and an ectopic left 
kidney (Shamseldin et al., 2012). Importantly, bi-
allelic loss-of-function mutations were detected in 
two other genes, MTBP and RGS3, in addition to 
XRCC2 (Shamseldin et al., 2012). The authors 
scrutinized these genes with bi-allelic mutations, 
since this inheritance pattern is typical of FA. 
XRCC2 emerged as a candidate FA gene, in part 
because another RAD51 paralog, RAD51C, had 
previously been identified as a FA gene (Vaz et al., 
2010). However, as loss-of-function mutations were 
present in other genes, XRCC2 could not be 
reliably established as causative for the clinical 
phenotype in this initial study. A subsequent study 
demonstrated that XRCC2 (FANCU) is indeed the 
20th FA gene based on the correction, following 
expression of XRCC2, of cellular phenotypes that 
are characteristic of FA cells (Park et al., 2016). 
These phenotypes included complementation of 
cellular hypersensitivity to MMC, correction of 
MMC-induced chromosome aberrations (total 
aberrations including breaks, gaps, radial and ring 
chromosomes, and number of radial chromosomes 
specifically), and MMC-induced cell cycle 
accumulation in G2-M (Park et al., 2016). 
However, the patient had normal blood counts and 
had not displayed cancer through age 7 (Park et al., 
2016; Shamseldin et al., 2012).  
To date, 22 FA or FA-like genes have been 
identified (Nepal et al., 2017). FA genes are 
autosomal recessive tumor suppressor genes, except 
for the X-linked FANCB and the autosomal 
dominant RAD51 (FANCR). The 
monoubiquitination of the FANCD2/ FANCI 
protein dimer is the central step in the FA pathway. 
FANC -A, -B, -C -E, -F, CC: TXT: -G ID: 295>, -
L, -M, UBE2T (FANC-T)  are early (or upstream) 
FA genes, since loss of function mutations in any of 
these genes results in defective monoubiquitination 
of FANCD2/I (Mamrak et al., 2017; Nepal et al., 
2017). Late/downstream FA genes, which are 
associated with normal monoubiquitination of 
FANCD2 and FANCI when mutated include: 
BRCA2 (FANCD1), BRIP1 (FANCJ), PALB2 
(FANCN), RAD51C (FANCO), RAD51 (FANCR), 
BRCA1 (FANCS), XRCC2 (FANCU), MAD2L2 
(FANCV/polTheta) and RFWD3 (FANCW). 
Typical of late/downstream FA genes, FA-U cells 
display defective assembly of RAD51 foci in 
response to DNA damage (Park et al., 2016).  
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The vast majority of FA patients have bi-allelic 
mutations in the upstream FA genes, notably 
FANCA, FANCC and FANCG, and display clinical 
features characteristic of FA. These include 
progressive bone marrow failure around 7.6 years 
of age, a variety of congenital anomalies, and a 
predisposition to acute myeloid leukemia as well as 
various solid tumors that occur in the second and 
third decade of life (Kutler et al., 2003). 
Microcephaly, short stature, skin pigmentation 
defects, hypogonadism, and radial ray anomalies, 
many of which were observed in the single FA-U 
patient identified until present, are among the 
congenital anomalies that are often observed. 
Endocrine abnormalities are also seen in a 
significant number of FA patients (Rose et al., 
2012).  
Certain other FA complementation groups such as 
FA-O, defined by RAD51C (FANCO) mutations, 
and FA-R, defined by heterozygous dominant-
negative RAD51 (FANCR) mutation, have been 
designated atypical FA (or FA-like) because of the 
absence of bone marrow failure and no increased 
incidences of cancer (Park et al., 2016). However, 
bone marrow failure and cancer are not always 
observed for every patient in each FA 
complementation group and the single FA-U patient 
identified so far has not reached the age at which 
these features are frequently observed (Kutler et al., 
2003). Therefore it is not yet clear whether or not 
patients with germ-line bi-allelic defects in XRCC2 
represent atypical FA. 
Breast Cancer 
Disease 
In a collaborative exome-sequencing study 
involving patients from the Netherlands, Spain and 
Australia, Park et al. identified 6 out of 1308 
patients with early-onset breast cancer as having 
likely deleterious mutations in XRCC2, while none 
of the 1,120 controls carried such a mutation. Two 
of the six mutations were frameshift mutations 
(p.Arg17* and p.Cys217*) and 4 of the 6 were 
missense alterations with single a.a. exchanges that 
were predicted by three algorithms to be associated 
with a loss-of-function (Park et al., 2012). As the 
frequency at which these variants occurred in breast 
cancer patients, as compared to controls, was 
statistically significant, XRCC2 was identified by 
the authors as a low frequency breast cancer 
susceptibility gene.  
However, no other study so far has confirmed 
mutation of XRCC2 as a significant cause of 
inherited breast cancer (Hilbers et al., 2016; Hilbers 
et al., 2012; Pelttari et al., 2015). For example, 
Hilbers et al. analysed the coding region of 3548 
non-BRCA1/2 familial breast cancer cases and 
1435 healthy controls (Hilbers et al., 2012). In the 
patient group, they detected only one patient with a 
protein truncation mutation and 20 patients with 
missense alterations, as compared to nine controls 
with missense variants. Importantly, in 2016, 
Hilbers et al. functionally analyzed all 
nonsynonymous coding variants from the two 
major studies published in 2012 (Hilbers et al., 
2012; Park et al., 2012). Out of 24 missense 
alterations, only four variants had a reduced 
functional activity with 50-75% rescue in two out 
of three assays (Hilbers et al., 2016).  
Finally, Decker et al. sequenced the XRCC2 coding 
region of 13,087 breast cancer patients and 5488 
healthy controls from the UK (Decker et al., 2017). 
Only 13 carriers of truncating XRCC2 variants 
were found, nine in breast cancer patients and four 
in controls. There were also no statistical 
differences for 32 rare missense variants between 
the patient and control groups. Thus these authors 
concluded that truncating/loss-of-function 
mutations in XRCC2 are not associated with an 
increased risk of breast cancer (Decker et al., 2017), 
and therefore germ-line mutation of XRCC2 is not 
a major cause of inherited breast cancer (Decker et 
al., 2017; Hilbers et al., 2012). 
Prognosis 
Because XRCC2 has an important role in HR, it is 
likely that tumors with loss-of-function of XRCC2 
may be particularly responsive to poly (ADP-
ribose) polymerase (PARP) inhibitors. In support of 
this possibility, FA cells from the FANCU 
complementation group, which have biallelic 
mutation of XRCC2, have increased sensitivity to 
the PARP inhibitor olaparib, as compared to 
complemented cells (Park et al., 2016). Thus, 
identification of breast cancer patients, and perhaps 
other cancer patients, with deleterious somatic 
variants of XRCC2 may be a basis for such 
personalized treatments. 
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